Author

Ana Paula Machado De Lacerda

EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Ana Paula Machado De Lacerda  et al.

EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES
EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Ana Paula Machado De Lacerda  et al.

EFFICACY OF INDUCTION UPADACITINIB THERAPY IN EAST ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFICACY OF INDUCTION UPADACITINIB THERAPY IN EAST ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Ana Paula Machado De Lacerda  et al.

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Ana Paula Machado De Lacerda  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: FINAL RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Ana Paula Machado De Lacerda  et al.

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

Ana Paula Machado De Lacerda  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Ana Paula Machado De Lacerda  et al.

Item 1 - 7 / 7
1